Results 71 to 80 of about 152 (86)

Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys

Human Gene Therapy, 2022
Francis Fonyuy Tukov, Keith Mansfield
exaly  

Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec

Molecular Therapy, 2023
Nishant Tiwari, Saunder Bernes, Ross Mangum   +2 more
exaly  

Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1

Current Medical Research and Opinion, 2021
Matthias Bischof, Maria Lorenzi, Eric Druyts   +2 more
exaly  

Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy

Brain and Development, 2022
Seungbok Lee, Yun Jeong Lee, Soo Yeon Kim   +2 more
exaly  

Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program

Pediatric Neurology, 2022
Deepa H Chand, Sandra P Reyna
exaly  

Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I

Journal of Clinical Medicine, 2021
Andrada Mirea, Elena-Silvia Shelby, Mihaela Badina   +2 more
exaly  

Onasemnogene abeparvovec for the treatment of spinal muscular atrophy

Expert Opinion on Biological Therapy, 2022
Hugh J Mcmillan, Crystal M Proud, Michelle A Farrar   +2 more
exaly  

Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec

Sleep Medicine, 2023
Carmen Leon-Astudillo, Mary Wagner, Carla D Zingariello   +2 more
exaly  

Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series

Journal of Pediatrics, 2023
Erin E Neil Knierbein
exaly  

Onasemnogene Abeparvovec-xioi: World’s most expensive and approved therapy for spinal muscular atrophy

NeuroPharmac Journal, 2021
Aslam Pathan
exaly